Bringing together the academic drug discovery community

Nature Reviews Drug Discovery

Volumn 12, Issue 11, 2013, Pages 811-812

  Slusher, Barbara S ^a   Conn, P Jeffrey ^b   Frye, Stephen ^c   Glicksman, Marcie ^d   Arkin, Michelle ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOLOGICAL PRODUCT; RPC 1063; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; BUDGET; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG PROGRAM; DRUG RESEARCH; FUNDING; GOAL ATTAINMENT; HIGH THROUGHPUT SCREENING; HUMAN; INTERNET; MULTIPLE SCLEROSIS; NOTE; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; TRANSLATIONAL RESEARCH; ULCERATIVE COLITIS; UNIVERSITY; VALIDATION STUDY;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; UNIVERSITIES;

EID: 84887076597     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4155     Document Type: Note

References (4)

1. Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nature Rev. Drug Discov.10, 328-329 (2011).
2. Arrowsmith, J. Trial watch: Phase III and submission failures: 2007-2010. Nature Rev. Drug Discov. 10, 87 (2011).
3. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).
4. Begley, C. G. & Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 483, 531-553 (2012).